Cidara Therapeutics Inc., a biotechnology company developing long-acting therapeutics designed to improve the standard of care for serious diseases, received a $20 million milestone payment from Melinta Therapeutics following the U.S. FDA approval of REZZAYO (rezafungin for injection), a novel, once-weekly echinocandin antifungal approved for the treatment of candidemia and invasive candidiasis. Last month, REZZAYO became the first new FDA-approved echinocandin in over a decade for once weekl...